Hunan Nucien Pharmaceutical Co Ltd
688189
Company Profile
Business description
Hunan Nucien Pharmaceutical Co Ltd is a pharmaceutical company integrating drug research and development, production and sales. The company focuses on anti-infection, cardio-cerebral vascular, anti-tumor and other pharmaceutical fields. The company's business scope includes the manufacturing and sales of chemical pharmaceutical preparations, chemical pharmaceutical raw materials, biological drugs, chemical reagents, and auxiliaries.
Contact
No. 1 Kangli Road
Liuyang Economic and Technological Development Zone
Hunan Province
Changsha510100
CHNSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
302
Stocks News & Analysis
stocks
Avoid this overvalued ASX healthcare share
Expensive healthcare share limited by its core addressable market.
stocks
AI driving growth for ASX tech share
ASX tech share raises funds to facilitate customer AI spend.
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,850.10 | 41.20 | 0.47% |
| CAC 40 | 8,203.43 | 4.14 | 0.05% |
| DAX 40 | 24,433.06 | 183.16 | -0.74% |
| Dow JONES (US) | 50,872.11 | 86.10 | 0.17% |
| FTSE 100 | 10,227.33 | 145.87 | -1.41% |
| HKSE | 24,565.90 | 91.16 | -0.37% |
| NASDAQ | 25,678.82 | 250.84 | -0.97% |
| Nikkei 225 | 64,887.16 | 529.47 | -0.81% |
| NZX 50 Index | 13,143.55 | 60.53 | -0.46% |
| S&P 500 | 7,386.65 | 19.08 | -0.26% |
| S&P/ASX 200 | 8,637.90 | 46.50 | 0.54% |
| SSE Composite Index | 4,010.03 | 50.69 | 1.28% |